Abstract: An apparatus and method for depositing a particulate containing composition onto mammalian skin such that when the particles contact the mammalian skin they have a momentum defined by ?vr, which is within the range of about 0.1 kg/ms??vr?about 12.0 kg/ms. The particles can be in the range of from about 10 nanometers to about 10 micrometers, in size. And the particles may be selected from the group consisting of titanium dioxide, zinc oxide, iron oxide, polyethylene, polypropylene, polyethylene terephthalate, polycarbonate, polyvinyl chloride, glass, silica and mixtures thereof. The particles are imbedded below the first layer of dead skin cells in the stratum corneum but they do not pass all the way through the stratum corneum into the living cells of the epidermis or dermis layers of the skin.

Abstract: Disclosed is a cosmetic composition capable of exhibiting various colors, including red, yellow and blue colors. The disclosed cosmetic composition comprises one or more pigments selected from among a natural pigment, a red, yellow or blue pearlescent pigment prepared by coating a natural pigment on a matrix, and a red, yellow or blue pearlescent pigment prepared by coating a metal oxide on a matrix, so that it is capable of exhibiting various colors.

Abstract: The present invention relates to a cosmetic composition in the form of an oil-in-water emulsion comprising: (A) at least 5% by weight of water; (B) at least 4% by weight of (C2-C8)alkylcellulose; (C) at least one hydrophilic gelling agent chosen from optionally modified polymers of natural origin; (D) at least one saturated or unsaturated, linear or branched C2-C8 polyol; (E) at least one hydrocarbon-based non-volatile first oil chosen from: —C10-C26 alcohols; —monoesters, diesters and triesters of a C2-C8 (poly)carboxylic acid and of a C2-C8 alcohol; —esters of a C2-C8 polyol and of one or more C2-C8 carboxylic acids; and (F) at least one non-volatile second oil chosen from silicone oils and/or fluoro oils or hydrocarbon-based oils other than the first oils (E). The invention also relates to a process for making up and/or caring for the lips, in which the abovementioned composition is applied.

Abstract: The invention relates to compositions, containing: at least one N-alkyl-N-acylglucamine as component A, dimethiconol as component B, at least one anionic surfactant as component C, optionally at least one betaine surfactant as component D, optionally at least one further surfactant as component E, water as component F, and optionally at least one further additive as component G, which compositions can be used as hair-washing agents.

Abstract: The present invention relates to the use of the inhibitor of the activity of the steroid sulfatase enzyme STX64 for the treatment of ageing and, therefore, to increase the longevity of individuals or improve their quality of life. It also relates to a cosmetic composition that comprises said inhibitor for that purpose.

Abstract: Dislosed are compositions comprising SkQ1 for protection of the skin from damage caused by free radicals and/or re active oxygen species.

Abstract: Processes wash out less color from artificially colored hair and comprise artificially coloring hair by applying a dye composition, comprising at least one hair dye, onto the hair, rinsing the dye composition off from the artificially colored hair, improving color stability of the artificially colored hair by washing the artificially colored hair, one or more times, with an aqueous cleansing composition, and drying the artificially colored hair or leaving the artificially colored hair to dry. The aqueous cleansing composition comprises at least three anionic surfactants and at least one non-ionic surfactant mixed together in water and is free of amphoteric surfactants.

Abstract: Compositions useful as dermal fillers and methods using such compositions to treat various skin and soft tissue conditions. The dermal fillers can comprise silk attached to hyaluronic acid using for example two cross linkers and can be used to treat of facial imperfections, facial defects, facial augmentations, breast imperfections, breast augmentations or breast reconstructions.

Abstract: The present invention relates to an inorganic material comprising particles of three-dimensional ordered macroporous structure comprising spherical pores, said pores having an average pore diameter ranging from 50 nm to 10 ?m, the pore diameter varying by no greater than 20%, the surface of said pores being coated by an absorber agent of the visible wavelength spectrum, said particles having an average largest dimension ranging from 1 to 50 ?m, and wherein said particles are coated with at least a hydrophobic component. The invention further relates to a process for preparing said inorganic material.

Abstract: Compositions and methods of treatment are disclosed using compositions of extracts from the fruit of the Synsepalum dulcificum tree, which when applied topically in mammals, can provide benefit for dermatological and joint conditions. The extracts also contain anti-inflammatory, antimicrobial and spermicidal activity in vitro.

Abstract: The invention relates to active ingredients capable of stimulating direct or indirect expression of type 2 human beta-defensins and/or type 3 human beta-defensins. The invention thus provides an active ingredient capable of stimulating direct or indirect expression of type 2 human beta-defensins and/or type 3 human beta-defensins, characterized in that the active ingredient does not cause any inflammatory, irritation or intolerance reactions. The invention also provides a screening method for the selection of such active ingredients. The invention is applicable to the preparation of cosmetic or pharmaceutical compositions containing such active ingredients.

Abstract: The present invention relates to a novel process for producing transmucosal pharmaceutical formulations and to formulations thus obtained. The process relates to the preparation of grains comprising a thermolabile substance as active ingredient, and consists in dissolving said substance in a ternary mixture composed of two amphiphilic binders, the melting point of which is between 40 and 60° C., and of an aqueous solvent such as, in particular, water, an aqueous-alcoholic solution or a water-soluble solvent. The grains thus obtained comprise a thermolabile active substance, two amphiphilic binders and an inert carrier. Use in obtaining translingual tablets wherein the thermolabile active substance is adrenalin.

Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficultly soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.

Abstract: The invention is directed to delivering therapeutic agents to the eye for the purpose of treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to delivering therapeutic agents to the eye for the purpose of treating ophthalmic disorders, diseases and injuries by targeted intranasal administration of the therapeutic agents. The invention is specifically directed to treating disorders, diseases and injuries of the cornea and ocular surface, treating retinal disorders, diseases and injuries and optic nerve disorders, diseases and injuries by targeted intranasal administration of the therapeutic agents.

Abstract: The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent.

Abstract: Described herein are materials and methods useful for the treatment of neurodegenerative disorders in a subject. Materials described herein include polysaccharide digestive products resulting from the enzymatic hydrolysis of low acyl gellan gum.

Abstract: The present disclosure provides for brewing apparatus, such as a disposable brewing pod, filter, beverage screen, or tea bag, treated with an oil-based solution comprising a lipid component; an emulsifier; and a pharmaceutical, holistic, or medical component. Brewing apparatus may be sprayed with a spray gun, such as a high volume low pressure spray gun, a precision bottle-top dispenser, or an automatic apparatus configured to apply an oil-based solution to the brewing apparatus. The brewing apparatus may be filled with a product to be brewed and packaged for individual use. The present disclosure additionally provides for a brewed drinkable product produced using brewing apparatus treated with an oil-based solution comprising a lipid component; an emulsifier; and a pharmaceutical, holistic, or medical component. The end product may be a hot or cold product.

Abstract: The present invention features a compressible delivery formulation for buccal delivery, dosage forms and methods of using the same for increasing testosterone levels in a subject. The formulation, dosage forms and methods comprise effective amounts of 3,4-divanillyltetrahydrofuran, 7-methoxyflavone, 7,8-benzoflavone.

Abstract: The present invention features a compressible delivery formulation for buccal delivery, dosage forms and methods of using the same for increasing testosterone levels in a subject. The formulation, dosage forms and methods comprise effective amounts of 3,4-divanillyltetrahydrofuran, 7-methoxyflavone, 7,8-benzoflavone, and L-Dopa.

Abstract: Provided herein are methods for preparing liposomes and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparation contains one or more active agents. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders.

Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Abstract: The present invention is directed to an excipient which can be used to manufacture tablets containing oily active ingredients such as oily drugs, and pharmaceutical compositions containing the same.

Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.

Abstract: Microbiota restoration therapy (MRT) compositions (e.g., oral MRT compositions) and methods for manufacturing MRT compositions are disclosed. An example method for manufacturing an MRT composition may include collecting a stool sample, purifying the stool sample to form a purified sample, stabilizing the purified sample to form a stabilized sample, converting the stabilized sample to a solid, adding one or more additives and/or excipients to the solid to form a treatment composition, and encapsulating the treatment composition.

Abstract: A targeted nanosphere and submicron controlled delivery system for topical and transdermal use is disclosed. The controlled delivery system can be used as a targeted drug delivery system. The controlled delivery system is a composition of active ingredients encapsulated in sub-micron spheres, optionally with an additional protective shell. The sphere includes a solid core and a semi-liquid shell. The size of the delivery system can be selected to supply the active ingredients in a targeted manner to the skin to treat skin conditions or through follicular penetration in order to treat for example, follicular diseases and stimulate or reduce hair growth.

Abstract: Compositions for delivery of growth factors needed for stable Tregs and methods of use thereof are provided. In preferred embodiments, the compositions can induce, increase, or enhance a functionally robust induced CD4 Treg population (e.g., Foxp3+ Treg) in vivo or ex vivo. The compositions generally include delivery vehicles including TGF-? and IL-2. Delivery vehicles include, for example, polymeric particles, silica particles, liposomes, or multilamellar vesicles. The TGF-? and IL-2 are typically co-loaded into, attached to the surface of, and/or enclosed within the delivery vehicle into the same particle for simultaneous co-delivery to cells such as T cells. Preferably the delivery vehicles are targeted to CD4. The compositions and cells treated therewith can be used in various methods of treating, for example, inflammation, inflammatory and autoimmune diseases and disorders, and inducing or maintaining tolerance including graft and transplant tolerance.

Abstract: Provided herein are silica shell particles modified on their surface with biomolecules, methods of making these particles, and methods of using these particles, e.g., in transfection methods, methods of inhibiting gene expression, and methods of delivering a therapeutic.

Abstract: Provided is a nanoparticle including a water-soluble protein, a glucan and a hydrophilic active agent, the glucan being at least partially cross-linked by a metaphosphate.

Abstract: Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C4-C20 alkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C4-C20 alkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.

Abstract: A composition for controlled release of an opioid from a pharmaceutical composition, the method comprises controlling the release of at least one opioid into an aqueous medium by erosion of at least one surface of a pharmaceutical composition comprising I) a matrix composition comprising a) polymer or a mixture of polymers, b) an opioid and, optionally, c) one or more pharmaceutically acceptable excipients, and (i) a coating. The matrix composition has a conus-like shape so the surface area exposed to the aqueous medium increases at least during initial erosion of the matrix composition, and the dissolution of the opioid—when tested in a Dissolution Test as described herein with or without application of sinkers—results in a zero order release of at least 80% of the opioid contained in the composition. Such compositions are especially suitable for controlled release of an opioid to obtain a delayed pead concentration and a prolonged therapeutically effective plasma concentration upon oral administration.

Abstract: Described herein are devices, compositions and methods relating to the production of high basis weight, non-woven nanofiber polymer fabrics. In certain embodiments, described herein are modifications to free-surface, needle-less or nozzle-less electrospinning devices that permit the production of such high basis weight, non-woven nanofiber polymer fabrics. Also described are the fabrics themselves and the fabrics including one or more biologically active agents to be released upon contact with a biological tissue. Such fabrics can incorporate biologically active agents in various combinations that permit, for example, burst and/or sustained release kinetics of one or more, preferably two or more biologically active agents.

Abstract: Transdermal delivery devices for the delivery of cannabidiol (CBD) are shown and described. In a reservoir-patch design, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In either design, the CBD may be provided as a pure compound or as a component of a cannabis oil.

Abstract: An edible composition includes safranal, crocin, picrocrocin, and a vitamin B complex including the vitamins B1, B2, B3, B6, B8, B9 and B12; which composition is advantageously intended for the treatment of onset phase of the depressive syndrome or the prevention of the state phase of the depressive syndrome in a subject.

Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth.

Abstract: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once—daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.

Abstract: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

Abstract: A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) one or more non-steroidal anti-inflammatory drugs (NSAIDs); a pharmaceutical salt comprising said components; a compound derived from said components; a pharmaceutical formulation and a dosage form comprising said combination, salt, or compound; as well as a method of treating pain, e.g. chronic or acute pain, in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.

Abstract: An anise flavored liquid medication. The liquid medication contains phenylephrine and an anethole analog that is substantially free of aldehyde groups. In one example, the anethole analog can be 1-methoxy-4-n-propylbenzene.

Abstract: The present invention relates to a combination formulation containing metformin for treating non-insulin-dependent diabetes and an HMG-CoA reductase inhibitor for treating dyslipidemia. The present invention provides a combination formulation and a method for preparing the combination formulation, wherein the combination formulation contains metformin and an HMG-CoA reductase inhibitor, and has effectively improved stability by blocking physical and chemical reactions between the active ingredients while securing the stable release of respective active ingredients.

Abstract: The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.

Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.

Abstract: The invention provides a gel patch comprising a support and an adhesive layer on the support, wherein the adhesive layer comprises 1.5 to 2.5 mass % of ketoprofen, 1.5 to 2.5 mass % of 4-tert-butyl-4?-methoxydibenzoylmethane and 12 to 18 mass % of propylene glycol, based on the total mass of the adhesive layer.

Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.

Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.

Abstract: The present invention provides for a novel lipokine, trans-C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, low concentrations of trans-C16:1n7-palmitoleate the serum indicates a risk of metabolic disease. Additionally, administering trans C16:1n7-palmitoleate to a subject (via pharmaceutical, nutraceutical, or other means), positively impacts glucose metabolism.

Abstract: The present invention relates to a method for producing and purifying SDA at high purity and/or high yield from a raw material such as anchovy oil. According to the present invention, when separating and purifying SDA from a raw material (e.g. anchovy oil) that includes SDA, high-quality, high-purity SDA is produced at a high recovery rate by using a combination of ethyl esterification and a silver nitrate treatment method. (1) A purification method selected from the group consisting of a thin-film vacuum superfractionation method, a simulated moving bed chromatography method, a urea addition method, and a molecular distillation method, and (2) an adsorbent treatment may be combined, as necessary.

Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 4-benzylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt or solvate thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 4-benzylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.

Abstract: Provided is a pharmaceutical composition for preventing or treating diabetic nephropathy, comprising a tensin like C1 domain containing phosphatase (TENC1) inhibitor as an active ingredient. A new target for treating diabetic nephropathy is presented by confirming that TENC1 expression is increased in kidney tissue of diabetes or a podocyte cell line to which a high blood glucose environment is given and experimentally proving that nephrin phosphorylation inhibited by the PTPase activity of TENC1 affects the permeability and mTORC1 signaling of the podocytes resulting in inducing podocyte hypertrophy.

Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such a